Physician profile
Moti Samaki
NPI 1477995868
$1,081.82
in general payments reported to CMS, 2019-2025
13 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $99.97 · 2021: $18.94 · 2022: $31.62 · 2023: $175 · 2024: $305 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613 · Education: $63.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.50 |
| Education | $63.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $171.10 | 2023-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $127.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $121.93 | 2024-2025 | |
| Amgen INC. | $112.26 | 2019-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $105.25 | 2023-2025 | Lupkynis |
| Travere Therapeutics, INC. | $90.21 | 2019-2025 | Filspari |
| Fresenius USA Marketing, INC. | $72.76 | 2019-2023 | Velphoro |
| Vifor Pharma, INC. | $64.68 | 2019-2021 | |
| Akebia Therapeutics INC | $60.18 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $59.81 | 2020-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $52.52 | 2023-2024 | Benlysta |
| Calliditas Therapeutics US INC. | $23.98 | 2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $19.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moti Samaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.